Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study

Epilepsy and Behavior

Volumn 19, Issue 3, 2010, Pages 352-358

  Biton, Victor ^a   Di Memmo, Juan ^b   Shukla, Rakesh ^c   Lee, Yeong Yeh ^d   Poverennova, Irina ^e   Demchenko, Vladislav ^f   Saiers, Jane ^g   Adams, Bryan ^h   Hammer, Anne ^h   Vuong, Alain ^h   Messenheimer, John ^h  

^a Arkansas Epilepsy Program   (United States)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

^d HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

^e SAMARA STATE MEDICAL UNIVERSITY   (Russian Federation)

^f Kyiv Psycho Neurological Clinic N 2   (Ukraine)

^g WriteMedicine Inc   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Epilepsy; Extended release formulation; Lamotrigine; Primary generalized tonic clonic seizures

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABSENCE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY GENERALIZED TONIC CLONIC SEIZURE; RANDOMIZED CONTROLLED TRIAL; SIMPLE PARTIAL SEIZURE; TONIC CLONIC SEIZURE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEIZURES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 78649904882     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.07.022     Document Type: Article

References (31)

1. LAMICTAL® (lamotrigine) prescribing information September 2006, GlaxoSmithKline, Research Triangle Park, NC.
2. Tompson D.J., Ali I., Oliver-Willwong R., et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia 2008, 49:410-417.
3. Naritoku D.K., Warnock C.R., Messenheimer J.A., et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007, 69:1610-1618.
4. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
5. Cramer J., Vachon L., Desforges C., Sussman N.M. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995, 36:1111-1117.
6. Garnett W.R. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000, 20:191S-199S.
7. Buck D., Jacoby A., Baker G.A., Chadwick D.W. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997, 6:87-93.
8. Cramer J.A., Glassman M., Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002, 3:228-242.
9. Williams J., Lawthom C., Dunstan F.D., et al. Variability of antiepileptic medication-taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry 2006, 77:481-484.
10. Brodie M.J., Richens A., Yuen A.W.C., et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995, 345:476-479.
11. Steiner T.J., Dellaportas C.I., Findley L.J. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999, 40:601-607.
12. Jawad S., Richens A., Goodwin G., et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989, 30:356-363.
13. Sander J.W.A.S., Patsalos P.N., Oxley J.R., et al. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990, 6:221-226.
14. Loiseau P., Yuen A.W.C., Duche B., et al. A randomized double-blind crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990, 7:136-145.
15. Schapel G.J., Beran R.G., Vajda F.J.E., et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993, 56:448-453.
16. Matsuo F., Bergen D., Faught E., et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993, 43:2284-2291.
17. Messenheimer J.A., Ramsay R.E., Willmore L.J., et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994, 35:1113-1121.
18. Gilliam F., Vazquez B., Sackellares J.C., et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998, 51:1018-1025.
19. Holmes G.L., Frank L.M., Sheth R.D., et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008, 82:124-132.
20. Motte J., Trevathan E., Arvidsson J.F.V., et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1998, 337:1807-1812.
21. Frank L.M., Enlow T., Holmes G.L., et al. Lamictal monotherapy for typical absence seizures in children. Epilepsia 1999, 40:973-979.
22. Biton V., Sackellares J.C., Vuong A., et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005, 65:1737-1743.
23. Schuirmann D.J. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharm Biopharm 1987, 15:657-680.
24. Fisch B.J. Generalized tonic-clonic seizures. The treatment of epilepsy: principles and practice 1996, 502-521. Williams and Wilkins, Baltimore. 2nd ed. E. Wyllie (Ed.).
25. Messenheimer J., Mullens E.L., Giorgi L., Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998, 18:281-296.
26. Biton V., Mirza W., Montouris G., et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001, 56:172-177.
27. Devinsky O., Vuong A., Hammer A., et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000, 54:973-975.
28. Ueberall M.A. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients: a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001, 46:63-67.
29. Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 2003, 44(Suppl. 7):44-50.
30. Biton V., Montouris G.D., Ritter F., et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999, 52:1330-1337.
31. Sullivan J.E., Dlugos D.J. Idiopathic generalized epilepsy. Curr Treat Options Neurol 2004, 6:231-242.